CAR7 Gene Therapy Shows Promise in T-Cell ALL

(MedPage Today) — The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions — up to 36 months in one case — in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), according…